(1R,21R,25S,28S,29S)-25-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-29-ethyl-7-methoxy-23,26-dioxo-2,22-dioxa-4,11,24,27-tetrazahexacyclo[25.2.1.03,12.05,10.013,15.019,21]triaconta-3,5(10),6,8,11-pentaene-28-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,21R,25S,28S,29S)-25-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-29-ethyl-7-methoxy-23,26-dioxo-2,22-dioxa-4,11,24,27-tetrazahexacyclo[25.2.1.03,12.05,10.013,15.019,21]triaconta-3,5(10),6,8,11-pentaene-28-carboxamide
• 化学式: C₄₁H₅₄F₂N₆O₉S
• 分子量: 845.0
• InChiKey: WWOUPPTZBDQNSZ-HKCYDGHZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  59
• 可旋转键数：
  9
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  204
• 氢给体数：
  3
• 氢受体数：
  13

文献信息

• [EN] INHIBITORS OF HEPATITIS C VIRUS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：GILEAD SCIENCES INC

  公开号：WO2014008285A1

  公开（公告）日：2014-01-09

  Compounds of Formula I are disclosed, As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

  化合物I的结构已经披露，以及其药用盐。还披露了使用这些化合物的方法和含有这些化合物的药物组合物。
• INHIBITORS OF HEPATITIS C VIRUS
  申请人：Gilead Sciences, Inc.

  公开号：US20160361375A1

  公开（公告）日：2016-12-15

  Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.